Nasivin Für Erwachsene Und Schulkinder (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nasivin Für Erwachsene Und Schulkinder, is an alpha‑adrenergic agonist presented as a nasal decongestant for nasal use. It relieves nasal congestion associated with the common cold, allergic rhinitis and sinusitis in adults and school‑age children.

GNH USA supplies Nasivin Für Erwachsene Und Schulkinder as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline Hydrochloride is an alpha‑adrenergic nasal decongestant used to alleviate congestion in the upper respiratory tract.

- Common cold: reduces nasal blockage and improves airflow. - Allergic rhinitis: alleviates swelling of nasal mucosa and congestion. - Sinusitis: helps relieve nasal congestion associated with sinus inflammation.

Oxymetazoline Hydrochloride may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation: mild burning or stinging sensation. - Dryness of nasal passages. - Sneezing. - Headache.

Serious or Rare Side Effects: - Rebound congestion (rhinitis medicamentosa) after prolonged use. - Hypertension or elevated blood pressure. - Severe allergic reaction such as anaphylaxis.

Use of Oxymetazoline Hydrochloride requires attention to several safety considerations.

- Age limitation: not recommended for children under 6 years without medical advice. - Pregnancy: safety not established; use only if clearly needed. - Cardiovascular disease: avoid in uncontrolled hypertension. - Concomitant MAO inhibitors: may increase vasoconstrictive effects. - Duration of use: limit to 3‑5 days to prevent rebound congestion. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Oxymetazoline Hydrochloride can interact with other medicines, requiring caution.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Sympathomimetic decongestants (e.g., pseudoephedrine): additive vasoconstriction. - Tricyclic antidepressants: potential for excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may reduce their effectiveness. - Beta‑blockers: may mask tachycardia. - Certain anesthetics: possible enhanced cardiovascular effects.